Effect and Efficacy of Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerosis

Harmonizing Optimal Strategy for Treatment of Coronary Atherosclerotic Lesions- Registry-based Study on the Effect and Safety of Xience Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerotic Lesions: HOST-Alpine Registry

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02845804

Acronym

HOST-ALPINE

Enrollment

1533

Registered

2016-07-27

Start date

2015-07-31

Completion date

2021-07-31

Last updated

2016-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Angina Pectoris, Coronary Artery Disease, Percutaneous Coronary Intervention

Keywords

coronary artery disease, percutaneous coronary intervention, everolimus-eluting stents

Brief summary

The objectives of this study are 1. To establish a prospective registry of the whole patients who received percutaneous coronary intervention with Xience Xpedition™/Alpine™ stent 2. To evaulate the long-term efficacy and safety of coronary stenting with the Xience Xpedition™/Alpine™ stent 3. To compare the long-term efficacy and safety of coronary stenting between the Xience Xpedition™/Alpine ™ stent and other contemporary drug-eluting stents which had established their own registry

Detailed description

Secondary endpoints of this study are Stent thrombosis-24 hours(acute), 30 days(subacute), 1 year(late), every 1 year till 3 years(very-late) after index PCI Target vessl failure Composite rate of cardiac death and any MI, 3 years Composite rate of all death and any MI Composite rate of all death, any MI, and any repeat revascularization Compliance and therapy interruptions with prescribed adjunctive antiplatelet therapy

Interventions

DEVICEAlpine

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* The patient agrees to participate in this study by signing the informed consent form. Alternatively, a legally authorized patient representative may agree to the patient's participation in this study and sign the informed consent form

Exclusion criteria

* There are no

Design outcomes

Primary

Measure	Time frame	Description
Target lesion failure	12 months	Composite of cardiac death, non-fatal target vessel-related myocardial infarction (MI), and ischemia-driven target lesion revascularization (TLR)

Secondary

Measure	Time frame	Description
Composite rate of cardiac death and myocardial infarction	12 months, 3 years	—
Composite rate of all-cause death and any myocardial infarction	12 months, 3 years	—
Composite rate of all-cause death and any myocardial infarction, and any repeat revascularization	12 months, 3 years	—
Target vessel failure	12 months	Composite of cardiac death, non-fatal target vessel related myocardial infarction, and ischemia-driven target vessel revascularization (TVR)
Clinical device and procedural success rate	intraoperative	—
Stent thrombosis	within 24 hours, 1 - 30 days, 31 days - 1 year, after 1 year	acute (within 24 hours), subacute (1 - 30 days), late (31 days - 1 year), very late (\>1 year)
Rate of compliance and interruptions with prescribed adjunctive antiplatelet therapy	12 months, 3 years	—

Countries

South Korea

Contacts

Primary ContactHyo-soo Kim, MD, PhD

hyosoo@snu.ac.kr+82-2-2072-2226

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026